Table 1 Italian data: incidence and direct costs of the NHS of BRCA mutated population31.
Data | Average | Best case | Worst case | |
|---|---|---|---|---|
BRCA1/2PV carriers in gen. pop. | 0.67% | 0.59% | 0.77% | |
Test eligible in pop gen (clinical criteria/family history) | 0.98% | 0.47% | 1.79% | 11, ABCFS |
Test positivity probability | 10.00% | 10.00% | 10.00% | |
BRCA1/2PV carriers in not eligible people | 0.58% | 0.51% | 0.68% | 3, ABCFS |
RRSO and RRM in carriers | 25.85% | 35.84% | 15.30% | |
RRSO only in carriers | 29.15% | 28.16% | 29.70% | |
RRM only in carriers | 21.15% | 20.16% | 18.70% | |
No prophylactic surgery in carriers | 23.85% | 15.84% | 36.30% | |
Both breast and ovarian cancer risk in carriers | 21.50% | 14.81% | 30.42% | |
Only ovarian cancer risk in carriers | 9.00% | 8.70% | 8.58% | |
Only breast cancer risk in carriers | 49.00% | 48.20% | 47.58% | |
No cancer probability in cancers | 20.50% | 28.31% | 13.42% | |
Post RRM: only breast cancer | 4.41% | 0.96% | 18.08% | |
Post RRM: only ovarian cancer | 28.56% | 23.20% | 27.44% | |
Post RRM: both breast and ovarian cancer | 1.94% | 0.30% | 11.56% | |
Post RRM: no cancer | 65.09% | 75.54% | 42.92% | |
Post RRSO: only breast cancer | 34.13% | 23.09% | 46.75% | |
Post RRSO: only ovarian cancer | 0.80% | 0.72% | 3.85% | |
Post RRSO: both breast and ovarian cancer | 0.42% | 0.22% | 3.95% | |
Post RRSO: no cancer | 64.65% | 75.97% | 45.45% | |
Post RRM and RRSO: only breast cancer | 3.49% | 0.62% | 15.82% | |
Post RRM and RRSO: only ovarian cancer | 1.18% | 0.93% | 6.46% | |
Post RRM and RRSO: both breast and ovarian cancer | 0.04% | 0.01% | 1.34% | |
Post RRM and RRSO: no cancer | 95.29% | 98.44% | 76.38% | |
Cost | ||||
Gynaecological visit and gynaecological US | 51.65 € | 51.65 € | 51.65 € | |
Genetic counselling and genetic testing (6blocks) | 1099,48 € | 1099.48 € | 1099.48 € | |
RRSO: DRG 359 | 1436.00 € | 1436.00 € | 1436.00 € | |
RRM: DRG 261 | 1960.00 € | 1960.00 € | 1960.00 € | |
Salpingo-Oophorectomy for ovarian K: DRG 357 | 6791.00 € | 6791.00 € | 6791.00 € | |
Mastectomy for breast K: DRG 258–257 | 3524.45 € | 3524.45 € | 3524.45 € | |
Chemotherapy | 2226.00 € | 2226.00 € | 2226.00 € | |
PARP inhibitor therapy | 82,344.00 € | 82,344.00 € | 82,344.00 € | |
Radiotherapy | 6000.00 € | 6000.00 € | 6000.00 € | |
Yearly follow-up BRCA+ | 198.20 € | 198.20 € | 198.20 € | |
Yearly follow-up BRCA−/unknown | 69.60 € | 69.60 € | 69.60 € | |
Age of consent: tests | 18 | 18 | 18 | |
Average age of BRCA+ cancer onset | 45 | 60 | 35 | |
Average number of years in FU: STEP 1 | 27 | 42 | 17 | |
Average number of years in FU: STEP 2 | 35 | 20 | 45 | |
Total follow up | 62 | 62 | 62 | |
Model exit age | 80 | 80 | 80 | |
Expected age of prophylactic surgery | 40 | 45 | 35 | |
